The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy.
Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G.
Serri O, et al.
Clin Endocrinol (Oxf). 2006 Apr;64(4):366-70. doi: 10.1111/j.1365-2265.2006.02469.x.
Clin Endocrinol (Oxf). 2006.
PMID: 16584506
Clinical Trial.
METHODS: Serum glucose, insulin, insulin resistance, lipids, high sensitivity C-reactive protein (hsCRP), interleukin (IL)-6, tumour necrosis factor (TNF)-alpha and soluble E-selectin (sELAM-1) serum levels were determined in 15 patients with hyperprolactinaemia at …
METHODS: Serum glucose, insulin, insulin resistance, lipids, high sensitivity C-reactive protein (hsCRP), interleukin (IL)-6, tumour …